Prognostic value of 18F‑FDG PET/CT in T‑Lymphoblastic lymphoma before and after hematopoietic stem cell transplantation

• N. Sun ^[2] ; W. Qiao ^[2] ; Y. Xing ^[2] ; T. Wang ^[2] ; J. Yang ^[1] ; J. Zhao ^[2]
  1. [1] Ningxia Medical University

     Ningxia Medical University

     China

     
  2. [2] Department of Nuclear Medicine, Shanghai General Hospital, Shanghai JiaoTo
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 8, 2021, págs. 1571-1576
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose We aimed to evaluate the prognostic value of 18F-FDG PET/CT in patients with relapsed or refractory T-Lymphoblastic lymphoma (T-LBL) undergoing hematopoietic stem cell transplantation (HSCT).

    Methods PET/CT was performed in 21 consecutive relapsed or refractory T-LBL patients scheduled for HSCT. All PET/ CT images were assessed using the Deauville criteria, and patients were divided into negative (Deauville≤3) and positive (Deauville>3) groups for comparison. The predictive value of sex, age, Ann Arbor stage, presence of B symptoms, lactate dehydrogenase level, presence of extranodal disease, and PET/CT results before and after HSCT were evaluated.

    Results Kaplan–Meier analysis showed that only PET/CT after HSCT (post-PET) was correlated with progression-free survival (PFS) (P=0.030). The Cox regression model also showed that the post-PET-positive group had a higher hazard ratio (HR) than the negative group (HR=3.884 and P=0.049). However, none of the evaluated factors were predictive of overall survival (OS).

    Conclusions Pre-PET cannot predict the PFS and OS of patients with T-LBL undergoing HSCT, which means that 18F-FDG PET/CT cannot be used for identifying patients who can beneft from HSCT. Post-PET is not predictive for OS in patients with T-LBL undergoing HSCT. However, post-PET showed strong correlations with PFS, which means that it may be useful for guiding subsequent clinical treatment decisions.